angiotensin ii has been researched along with Parkinson Disease in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Labandeira, CM; Labandeira-Garcia, JL; Lanciego, JL; Pedrosa, MA; Quijano, A; Rodriguez-Perez, AI; Sanchez-Andrade, M; Suarez-Quintanilla, JA; Valenzuela, R | 1 |
| Gao, Q; Jiang, T; Ou, Z; Shi, JQ; Tian, YY; Wu, L; Zhang, YD; Zhou, JS | 1 |
| Harding, JW; Kawas, LH; Wright, JW | 1 |
| Aboud, O; Biedermann, J; Gentleman, SM; Griffin, WS; Mrak, RE; Palmer, QD; Zawada, WM | 1 |
| Guerra, MJ; Labandeira-Garcia, JL; Lanciego, JL; Rodriguez-Perez, AI; Valenzuela, R; Villar-Cheda, B | 1 |
| Guerra, MJ; Labandeira-Garcia, JL; Rodriguez-Perez, AI; Valenzuela, R; Villar-Cheda, B | 1 |
| Baltatu, OC; Guerra, MJ; Labandeira-Garcia, JL; Muñoz, A; Rodríguez-Pallares, J; Valenzuela, R; Villar-Cheda, B | 1 |
| Guerra, MJ; Joglar, B; Labandeira-Garcia, JL; Parga, JA; Rodriguez-Pallares, J | 1 |
| Grammatopoulos, TN; Hyman, BT; Outeiro, TF; Standaert, DG | 1 |
| Allen, AM; Chai, SY; Donnan, GA; Ireton, J; Kaczmarczyk, S; Kalnins, R; MacGregor, DP; Mendelsohn, FA; Richardson, K | 1 |
| Nelson, SR; Walaszek, EJ | 1 |
| Siegenthaler, W; Werning, C | 1 |
| Barbeau, A; Boucher, R; Brossard, Y; Cuche, JL; Genest, J; Kuchel, O | 1 |
| Klasen, H; Pontzen, W; Umbach, W | 1 |
| Nakano, KK; Sullivan, JM; Tyler, HR | 1 |
| Hoeldtke, R | 1 |
4 review(s) available for angiotensin ii and Parkinson Disease
| Article | Year |
|---|---|
The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.
Topics: Alzheimer Disease; Angiotensin II; Animals; Humans; Memory Disorders; Parkinson Disease; Receptors, Angiotensin; Renin-Angiotensin System | 2015 |
Pharmacology of the central nervous system.
Topics: Abnormalities, Drug-Induced; Acetylcholine; Adrenocorticotropic Hormone; Amphetamine; Anger; Angiotensin II; Animals; Avoidance Learning; Behavior, Animal; Cats; Central Nervous System; Central Nervous System Diseases; Chick Embryo; Desipramine; Dogs; Guanethidine; Guinea Pigs; Humans; Hypnotics and Sedatives; Imipramine; Memory; Mice; Norepinephrine; Parkinson Disease; Phenacetin; Phenothiazines; Phenoxybenzamine; Rabbits; Rats; Reserpine; Serotonin; Sleep; Sleep, REM; Synapses; Synaptic Transmission; Tetrodotoxin; Theophylline | 1968 |
[Renin-angiotensin-aldosterone system from the clinical viewpoint].
Topics: Addison Disease; Aldosterone; Angiotensin II; Cushing Syndrome; Female; Humans; Hyperaldosteronism; Hypertension, Renal; Juxtaglomerular Apparatus; Male; Parkinson Disease; Pheochromocytoma; Pregnancy; Pregnancy Complications; Renin; Water-Electrolyte Balance | 1970 |
Catecholamine metabolism in health and disease.
Topics: Angiotensin II; Bacteria; Brain; Catecholamines; Diet; Dopamine; Dysautonomia, Familial; Humans; Hypertension; Hypopituitarism; Intestines; Neurons; Norepinephrine; Parkinson Disease; Phenylketonurias; Renin; Stomach; Sympathetic Nervous System | 1974 |
12 other study(ies) available for angiotensin ii and Parkinson Disease
| Article | Year |
|---|---|
AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Autoantibodies; Dopamine; Dopaminergic Neurons; Endothelial Cells; Humans; Inflammation; Metabolic Syndrome; Neuroinflammatory Diseases; Parkinson Disease; Rats; Receptor, Angiotensin, Type 1 | 2023 |
Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic parkinsonian behaviors in a rat model of Parkinson's disease.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Behavior, Animal; Benzimidazoles; Disease Models, Animal; Dopaminergic Neurons; Humans; Male; Oxadiazoles; Parkinson Disease; Rats; Receptor, Angiotensin, Type 1; Substantia Nigra | 2017 |
Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation.
Topics: Aged; Aged, 80 and over; Angiotensin II; Case-Control Studies; Caspase 3; Disease Progression; Dopaminergic Neurons; Female; Guanosine; Humans; Male; NADPH Oxidases; Oxidative Stress; Parkinson Disease; Receptor, Angiotensin, Type 1; Substantia Nigra | 2015 |
Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Cell Death; Dopamine; Estradiol; Estrogens; Female; Humans; Neuroglia; Neurons; Ovariectomy; Oxidopamine; Parkinson Disease; Peptidyl-Dipeptidase A; Postmenopause; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Substantia Nigra; Tetrazoles | 2010 |
Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Dopaminergic Neurons; Inflammation Mediators; Interleukin-1beta; Male; Molecular Targeted Therapy; NADPH Oxidases; Nerve Degeneration; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Substantia Nigra; Tetrazoles; Tumor Necrosis Factor-alpha | 2012 |
Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Angiotensin II; Animals; Corpus Striatum; Disease Progression; Dopamine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Reserpine; Substantia Nigra | 2010 |
Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease.
Topics: Aging; Angiotensin II; Animals; Cells, Cultured; Dopaminergic Neurons; Fluorescence; Humans; Immunohistochemistry; Male; Oxidative Stress; Oxidopamine; Parkinson Disease; Potassium Channels; Rats; Reactive Oxygen Species; Reference Values; Renin-Angiotensin System; Sensitivity and Specificity; Substantia Nigra | 2012 |
Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.
Topics: alpha-Synuclein; Angiotensin II; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Imidazoles; Immunoblotting; Inclusion Bodies; Losartan; Parkinson Disease; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Vasoconstrictor Agents | 2007 |
Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
Topics: Aged; Aged, 80 and over; Angiotensin II; Corpus Striatum; Dopamine; Female; Humans; Male; Neurons; Parkinson Disease; Putamen; Receptors, Angiotensin; Substantia Nigra | 1992 |
Dopamine and blood pressure.
Topics: Aldosterone; Angiotensin II; Basal Ganglia; Blood Pressure; Circadian Rhythm; Dopamine; Humans; Kidney; Norepinephrine; Parkinson Disease; Renin | 1970 |
Plasma renin activity (PRA) in Parkinson's disease before and after stereotaxic operation.
Topics: Angiotensin II; Blood Pressure; Blood Protein Electrophoresis; Dopamine; Hematocrit; Humans; Natriuresis; Parkinson Disease; Potassium; Renin; Sodium; Stereotaxic Techniques; Thalamus | 1972 |
Plasma renin activity during levodopa therapy. Significance of long- and short-term treatment.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Animals; Blood Pressure; Diet; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Disease; Posture; Potassium; Rats; Renin; Sodium; Time Factors | 1973 |